Skip to main content
PAS 2025 Meeting Main banner
Final Program


Schedule at a Glance
Icon Legend
Presentation Icons
Ticketed Event
Ticketed Event
Norman J. Siegel New Member Outstanding Science Award
Norman J. Siegel New Member Outstanding Science Award
John Howland Award
John Howland Award
Mary Ellen Avery Award
Mary Ellen Avery Award
SPR Thomas A. Hazinski Distinguished Service Award
SPR Thomas A. Hazinski Distinguished Service Award
SPR Douglas K. Richardson Award for Perinatal and Pediatric Healthcare Research
SPR Douglas K. Richardson Award for Perinatal and Pediatric Healthcare Research
PROSPER Diversity Award
PROSPER Diversity Award
ASPN Founders’ Award
ASPN Founders’ Award
David G. Nichols Health Equity Award
David G. Nichols Health Equity Award
ASPN Mid-Career Award
ASPN Mid-Career Award
Awarded Part 4 Maintenance of Certification (MOC) Credit
Awarded Part 4 Maintenance of Certification (MOC) Credit
Poster Icons
Awarded Part 4 Maintenance of Certification (MOC) Credit
Awarded Part 4 Maintenance of Certification (MOC) Credit
ViewAttendees 4

Public Health & Prevention

Public Health & Prevention 1

A Randomized Study to Evaluate the Efficacy of a Cell-Based Quadrivalent Influenza Vaccine Compared to a Non-Influenza Vaccine in Children 6 Months to 47 Months of Age

Sunday, April 27, 2025
11:15am – 11:30am HST
Location:  Convention Center: 326
Publication Number: 3150.3
Airi Poder, Clinical Research Centre, Tartu, Tartumaa, Estonia; Anna Lisa T. Ong-Lim, College of Medicine - Philippine General Hospital, University of the Philippines Manila, Manila, National Capital Region, Philippines; Vince Matassa, CSL Seqirus, Melbourne, Victoria, Australia; Esther Heijnen, CSL, Amsterdam, Noord-Brabant, Netherlands; Matthew Hohenboken, CSL Seqirus, Albany, NH, United States; Deborah C. Molrine, CSL, Waltham, MA, United States

    Presenting Author(s)

  • Deborah C. Molrine, MD MPH (she/her/hers)

    Clinical Program Director
    CSL
    Waltham, Massachusetts, United States

    Slides Video
Disclosure(s):
Deborah C. Molrine, MD MPH: CSL Seqirus (Ongoing) (Products/Services: Employment with an ineligible company, Ownership Interest including individual stocks, stock options, excluding diversified mutual funds)